Double-headed arrow (between “Obstructive sleep apnea syndrome” and “Obesity”): This indicates a bidirectional relationship between Obstructive sleep apnea syndrome and obesity. Intermittent hypoxia ...
Mark Bleackley, PhD, chief scientific officer of Incannex, discusses in further detail the need for a pharmacotherapy like IHL-42X in obstructive sleep apnea (OSA) and the medication's underlying ...
Double-headed arrow (between “Obstructive sleep apnea syndrome” and “Obesity”): This indicates a bidirectional relationship between Obstructive sleep apnea syndrome and obesity. Intermittent hypoxia ...
An epilepsy drug sold in Europe as Ospolot and also known as sulthiame showed promise in reducing sleep disordered breathing and other symptoms of obstructive sleep apnea (OSA), based on data from ...
Increased risk of obstructive sleep apnea as measured by the STOP-Bang score is associated with a higher prevalence of glaucoma and increased intraocular pressure. Increased obstructive sleep apnea ...
Patient dosing completed in Phase 2 portion of Phase 2/3 RePOSA study evaluating IHL-42X oral treatment for OSA. End-of-study follow-up assessments on track for completion by May 17, 2025. Topline ...
boy laying in bed The comorbid presence of central apnea has been identified by multiple researchers as predictive of SUDEP. Sudden unexpected death in epilepsy (SUDEP) has an estimated incidence rate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results